The positive correlation between PD-L1 and VEGF expression has potential clinical significance for the treatment of glioma, because anti-angiogenic agents targeting VEGF or its receptors did not yield exciting results in glioma clinical trials, implying that other factors are involved in the development of glioma [43, 44]. This evidence concerns the gene VEGFA and central nervous system cancer.